BIBLIOGRAFÍA:

1. Smith I. Goals of treatment for patients with metastatic breast 21. Vogel C, O’Rourke M, Winer E, et al. Vinorelbine as first-line.
2. Gralow JR. Optimizing the treatment of metastatic breast can- of age or older. Ann Oncol 1999; 10 (4): 397-402
3. Guarneri V, Conte PF. The curability of breast cancer and the effective palliative regimen after failure with anthracyclines treatment of advanced disease. Eur J Nucl Med Mol Imaging and taxanes in metastatic breast carcinoma.
4. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4(4): 253-65.
5. Budman DR. Vinorelbine (Navelbine): a third-generation vinca alkaloid. Cancer Invest 1997; 15(5): 475-90.
6. Schrijvers DL. Extravasation: a dreaded complication of chemotherapy.Ann Oncol 2003; 14(Supl. 3): 26.
7. Griffin L. On the receiving end V: patient perceptions on the side effects of cancer chemotherapy in 1993. Ann Oncol 1996;7: 189-95.
8. Liu G, Franssen E, Fitch MI, et al. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol 1997; 15: 110-5.
9. Marty M, Fumoleau P, Adenios A, et al. Oral vinorelbine pharmacokinetics and absolute bioavailability study in patients withsolid tumors. Ann Oncol 2001; 12: 1643-9.
10. Bonneterre J, Chevalier B, Focun C, et al. Phase I and pharmacokinetic study of weekly oral therapy with vinorelbine in patients with advanced breast cancer Ann Oncol 2001; 12: 1683-91
11. Freyer G, Delozier T, Lichinester M, et al. Phase II study of oral vinorelbine in fisrt-line advanced breast cancer chemotherapy. J Clin Oncol 2003; 21: 35-40.
12. Amadori D, Koralewski P, Tekiela A, et al. Efficacy and safety of navelbine oral (NVBO) in first line metastatic breast cancer metastatic breast cancer (MBC) [abstract no. 1939]. Eur J Cancer 2001; 37 Suppl. 6: 195.
13. Baweja M, Suman VJ, Fitch TR, et al. Phase II trial of oral vinorelbine for the treatment of metastatic breast cancer in patients > 65 years of age: an NCCTG study. Ann Oncol 2006; 17: 623-9.
14. Sawada N, Fujimoto-Ouchi K, Ishikawa T, Tanaka Y, Ishituka H: Antitumour activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models., Proc Am Assoc Cancer Res, 2002.
15. Anton A, Lluch A, Casado A, et al. Phase I-II study of oral vinorelbine (NVBO ) and capecitabine (X) in metastatic breast cancer (MBC): Results of the phase I trial. J Clin Oncol 26: 2008 (May 20 suppl; abstr 1105).
16. Ghosn M et al. Final results of a phase II study of vinorelbine in combination with capecitabine as first line chemotherapy for metastatic breast cancer (MBC). Proc. Am. Soc. Clin. Oncol. 2003;abst. 270.
17. Delcambre C, Bourgeois H, Veyret C, Levy C. et al. A phase I/II study of capecitabine combined with oral vinorelbine (N) as first- or second-line chemotherapy in patients (pts) with locally advanced Breast Cancer (MBC). Breast Cancer Res. Treat. 2005; 94 (suppl. 1), S67-abst. P1081.
18. Nolé F, Catania C, Sanna G, et al. Phase II study with dose finding of oral vinorelbine in combination with capecitabine as first line chemotherapy of metastatic breast cancer (MBC): preliminary results of the phase II part of the study. Eur. J. Can. 2006 (Suppl. 4); abst. 408.
19. Finek K, Holubec L, Elgrova L, et al. The effect of oral vinorelbine and capecitabine in patients with metastatic breast cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol. 2006
20. Tubiana-Mathieu N, Bougnoux P, Becquart D, Chan A, Majois F, Espie M, Llombart A, Villanova G, Conte PF: An international phase ii study of an all-oral combination of oral vinorelbine (nvbo) and capecitabine (x) in her2-negative metastatic breast cancer (mbc): Latest results with a median follow-up of 37.7 months.: ESMO, 2008.
21. Nole F, Crivellari D, Mattioli R, Pinotti G, Foa P, Verri E, Fougeray R, Brandely M, Goldhirsch A: Phase II study of an all-oral combination of vinorelbine with capecitabine in patients with metastatic breast cancer. Cancer Chemother Pharmacol 2009.
22. Blajman C, Balbiani L, Block J, et al. A prospective, randomized phase III trial comparing combination chemotherapy with cyclophosphamide, doxorubicin, and 5 fluorouracil with vinorelbine plus doxorubicin in the treatment of advanced breast carcinoma. Cancer 1999; 85: 1091-7.
23. Eljersten B, Mouridsen HT, Langkjer ST, et al. Phase III study of intravenous vinorelbine in combination with epirubicin versus epirubicin alone in patients with advanced breast cancer: a Scandinavian Breast Group trial (SBF9403). J. Clin. Oncol. 2004; 22: 2313-20.
24. Serin D, Verill M, Jones A, et al. Vinorelbine alternating oral and intravenous plus epirubicin in first-line therapy of metastatic breast cancer: results of a multicentre phase II study. Brit. J. Cancer2005; 92: 1989-96.
25. Campone M et al., Combination of vinorelbine (VRL) alternating I.V. and oral in combination with docetaxel (DTX) as first line chemotherapy (CT) of metastatic breast cancer (MBC) – Efficacy results. EBCC 2006.
26. Felici A, Russillo M, Di Segni S et al. Dose-escalating study of continuative low dose of oral vinorelbine in patients with advanced breast cancer..J Clin Oncol 27:15s, 2009 (suppl; abstr 1128)
27. Kalykaki A, Agelaki S, Kotsakis A et al.A phase I study of oral metronomic vinorelbine plus capecitabine in patients with metastatic breast cancer. J Clin Oncol 27:15s, 2009 (suppl; abstr 1127).
28. Addeo R, Faiola V, Cennamo G, et al. A novel metronomic schedule of oral vinorelbine for the treatment of metastatic breast cancer in elderly patients: A phase II trial. J Clin Oncol 27:15s, 2009 (suppl; abstr 1085)
29. Locatelli M. A, Curigliano G, Fumagalli L et al. Bevacizumab and oral chemotherapy for patients with lymphangitic breast cancer: A phase II randomized study of bevacizumab with sequential versus concurrent oral vinorelbine plus capecitabine. J Clin Oncol 27:15s, 2009 (suppl; abstr 1031).
30. Lotz J, Husseini F, Finck, M, et al French experience of patient management when receiving oral vinorelbine chemotherapy (NVBO) for metastatic breast cancer: Final results of a prospective observational survey on practices. J Clin Oncol 27, 2009 (suppl; abstr e12013)
31. Nole F, Munzone E, Bertolini F, et al. Circulating endothelial cells (CECs), progenitors (CEPs), and circulating tumor cells (CTCs) for prediction of response in patients with advanced breast cancer (ABC) receiving metronomic oral vinorelbine (oV): Preliminary results. J Clin Oncol 27, 2009 (suppl; abstr e14572)